Denosumab Products (Prolia) Prior Authorization
Customize your policy alerts
Sign up for Cigna Policy IP0331 alerts
Get alerted when Policy IP0331 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and medical-necessity coverage for Prolia and specified denosumab biosimilars used to treat osteoporosis or cancer-treatment-related bone loss. It applies to health benefit plans administered by Cigna Companies, subject to the member’s benefit plan, applicable law, and any controlling coverage mandate.
Treatment of bone loss in patients with prostate cancer receiving androgen deprivation therapy was added as an approval condition with a 1-year approval period and dosing of 60 mg subcutaneously every 6 months.
Increasing bone mineral density in patients with breast cancer was added as an approval condition with a 1-year approval period and dosing of 60 mg subcutaneously every 6 months.
Additional denosumab biosimilars, including Enoby, Bosaya, Osvyrti, and products represented by the listed billing codes, were added with the same medical-necessity criteria as Prolia and other covered biosimilars.
Preferred product criteria were removed from the coverage policy.
Concurrent use with other denosumab products was added as a condition not recommended for approval.
An exception was added allowing a postmenopausal osteoporosis patient with a very low T-score below -3.0 to bypass the bisphosphonate trial.
Additional billing codes for denosumab products and biosimilars were added or updated.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.